CN105193886A - Preparation method and medical application of blood-fat-reducing active component - Google Patents
Preparation method and medical application of blood-fat-reducing active component Download PDFInfo
- Publication number
- CN105193886A CN105193886A CN201410287181.0A CN201410287181A CN105193886A CN 105193886 A CN105193886 A CN 105193886A CN 201410287181 A CN201410287181 A CN 201410287181A CN 105193886 A CN105193886 A CN 105193886A
- Authority
- CN
- China
- Prior art keywords
- radix
- active component
- acanthopanacis senticosi
- caulis acanthopanacis
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to the field of medical technologies, in particular to a preparation method and medical application of a blood-fat-reducing active component. The active component is a component which is obtained from eleutherococcus senticosus serving as an araliaceae acanthopanax plant in an extracted and separated mode and restrains activity of diacylglycerol acyltransferase (DGAT1). Repeated in-vitro DGAT1 restraining experiments show that the component has obvious DGAT1 restraining activity, can be applied to preparing medicine for preventing and treating hyperlipidemia, atherosclerosis, obesity and complications and has important meaning for developing and utilizing medicinal plant resources in China.
Description
Technical field
The present invention relates to a kind of Radix Et Caulis Acanthopanacis Senticosi active component for the treatment of hyperlipidemia, and disclose its active component with effect for reducing blood fat and extracting method, additionally provide its medical application simultaneously.Active component of the present invention is through repeatedly external diacylglycerol acyltransferase 1(DiacylgycerolAcyltransferase; DGAT1) experiment shows; this active component can significantly suppress DGAT1 active; preparing blood fat reducing, atherosclerosis, falling in body weight and complication medicine and apply, Chinese medicine and pharmacy technical field can be related to.
Background technology
Hyperlipidemia mainly refers to by serum total cholesterol (TC) or triacylglycerol (TG) level is too high and (or) Serum High-Density Lipoprotein-Cholesterol (HDL-C) level is too low, and the disease of a series of serious harm healths caused.Along with the raising of people's living standard, living-pattern preservation, the arrival of aged tendency of population, the crowd suffering from hyperlipidemia constantly increases.Research shows, hyperlipidemia causes atherosclerotic arch-criminal, and arteriosclerosis is the arch-criminal causing cardiovascular and cerebrovascular disease (angina pectoris, myocardial infarction, hemiplegia).The M & M being caused cardiovascular and cerebrovascular disease by hyperlipidemia presents the trend increased gradually in the world, and at present, the whole world has 1,500 ten thousand people to die from cardiovascular and cerebrovascular disease, far away higher than number of cancer deaths every year.
Diacylglycerol acyltransferase (DiacylgycerolAcyltransferase, DGAT) participates in the deposition of lipid metabolism and lipid.The gene of this enzyme of encoding has DGAT1 and DGAT2, and the former belongs to cholesterol acyltransferase (Acyl-CoA:cholesterolacyltransferase, ACAT) gene family in S-acetyl-coenzyme-A, and the latter belongs to another independently gene family.DGAT1 can the coenzyme A of catalyzing acyl and DG synthesis TG, and TG in vivo surplus gather diseases such as can causing atherosclerosis, obesity, diabetes, non-alcoholic fatty liver disease.Therefore, by finding selectively acting in the inhibitor of DGAT1, reduce the formation of TG in serum, thus regulate disorders of lipid metabolism, reduce body weight, become the new way of more and more concerned Prevention and Curation hyperlipidemia.[the ZhaoG such as Zhao, SouersAJ, VoorbachM, etal.ValidationofdiacylglycerolacyltransferaseIasanovelt argetforthetreatmentofobesityanddyslipidemiausingapotent andselectivesmallmoleculeinhibitor.JMedChem, 2008,51:380-3] report that the DGAT1 of micromolecular compound 4a to Mus and people for DGAT1 chemosynthesis has stronger inhibition, IC
50be respectively 24nmol/L, 7nmol/L, oral administration of compound 4a can make the obesity mice of diet induced lose weight, and liver TG obviously reduces, and does not affect food ration, and in surrounding, body weight does not have a rebound.[the BirchAM such as Birch, BirtlesS, BuckettLK, etal.Discoveryofapotent, selective, andorallyefficaciouspyrimidinooxazinylbicyclooctaneaceti caciddiacylglycerolacyltransferase-1inhibitor.JMedChem, 2009,52 (6): 1558-68] obesity mice of oral effective DGAT1 inhibitor (15nmol/L) to diet induced reported also has antiobesity action.Many pharmaceutical manufacturers also carry out preclinical study for DGAT1.
2006, the DGAT1 inhibitor B AY74-4113 of Pfizer was in I clinical trial phase; 2009, the DGAT1 inhibitor of Novartis entered II clinical trial.DGAT1 becomes the medicine focus of the diseases such as research hyperlipidemia, obesity, disorders of lipid metabolism, diabetes gradually.Be not also at present the natural blood lipid-lowering medicine listing of target spot with DGAT1, this for we find from natural resources efficiently, highly selective micromolecule DGAT1 inhibitor provides opportunity.
The Radix Et Caulis Acanthopanacis Senticosi that the present invention relates to (
radixAcanthopanacisSenticosl) belonging to Araliaceae Acanthopanax, primary growth is in the woods of hillside and in the shrubbery of roadside; Often there is cultivation in medicine garden.Be distributed in Central China, East China, south China and southwest.Be mainly used in the effects such as antitumor, resisting fatigue, reduction whole blood viscosity, atherosclerosis formation.
The present invention is separated first and obtains having the active component suppressing DGAT1 from Radix Et Caulis Acanthopanacis Senticosi, through repeatedly pharmacological experiment study, find that this active component has and significantly suppress the active and effect for reducing blood fat of DGAT1, by literature search, have no such plant and there is report in this respect.
Summary of the invention
The invention provides Radix Et Caulis Acanthopanacis Senticosi alcohol extraction active component with effect for reducing blood fat and preparation method thereof, its objective is and be used for the treatment of hyperlipidemia, atherosclerosis, obesity and complication disease.
Another object of the present invention is to provide the active component that is defined as above and is producing for diacylglycerol acyltransferase 1(DGAT1) application in inhibitor.
The preparation method of active component of the present invention, comprises the following steps:
By 75% soak with ethanol 1 hour of Radix Et Caulis Acanthopanacis Senticosi 1-2 times amount, utilize ultrasonic extraction 1-3 hour, sucking filtration also collects filtrate; Filtrate concentrates with Rotary Evaporators, collects concentrated solution, cools, add 2-3 times of water gaging and stir, room temperature leaves standstill 24 hours, separates out precipitation, and filter or centrifuging and taking precipitation, precipitate is placed in surface plate and heats, removing second alcohol and water, until without alcohol taste, obtains Radix Et Caulis Acanthopanacis Senticosi ethanol extract; By Radix Et Caulis Acanthopanacis Senticosi ethanol extract through 150 μm of reversed phase chromatography, in order to methanol/water (V/V, 0:10-10:0) for mobile phase carries out gradient elution, the separation component collected utilizes inverse thin layer chromatography to detect, the identical separation component of composition merges, concentrate after obtain 10 separation components (F1-F10).By F2 component again through HP-20 macropore chromatograph, in order to methanol/water (V/V, 0:10-10:0) for mobile phase carries out gradient elution, collect the separation component of methanol/water (V/V, 3:7), concentrated after obtain Radix Et Caulis Acanthopanacis Senticosi active component.
Hypolipidemic activity component of the present invention can be applied in Prevention and Curation hyperlipidemia, atherosclerosis, obesity and complication medicine thereof.
Test philosophy: use expression at the mankind DGATl of insect cell membrane as enzyme source, diacylglycerol (Diacylgycerol, DAG) forms triacylglycerol (triacylgycerol, TG) with fatty acid acyl coenzyme A under the effect of DGAT.Glyceroyl-coenzyme A is used
14c labelling, detects the radioactivity of product by liquid scintillation photographic process and observes the activity change of enzyme and compound to the suppression situation of enzymatic activity.
following test example shows the pharmacologically active of active component of the present invention
test example 1
active component of the present invention suppresses DGAT1 activity test
Experimental technique: the vitro detection of DGATl inhibitor uses expression at the mankind DGATl of insect cell membrane as enzyme source.The sf9 cell recombinant baculovirus comprising mankind DGATl coded sequence is infected, gathers after 48 hours.Cell is dissolved by ultrasonic dissolution method, and under 4 DEG C of conditions, with 28000rpm rotating speed centrifugalize 1 hour in 40% sucrose solution, obtains described barrier film.Collect, clean intercellular barrier film fragment and store in liquid nitrogen.
DGAT1 Activity determination by revise Coleman (Coleman) described by method carry out (methodsinEnzymology1992,209,98-102).Comprise in reaction system, 10 μm of ol/L samples, the 0.4 μ g memebrane protein that said method obtains, 5mmol/LMgCl
2and 1.2mmol/L
sn-1,2-DG-glycerol, detects volume to 200 μ L with distilled water adjustment is total, cultivates in test tube.By adding 100 μm of ol/L in above-mentioned system
14glyceroyl-the coenzyme A (0.05 μ Ci) of C labelling reacts, and under 25 DEG C of conditions, carry out gentle of short duration concussion.By adding 1.5mL2-propanol after 30min: heptane: water (80:20:2) cessation reaction.Reaction adds l.0mL heptane and 0.5mL carbonate Slow and rushes liquid (0.1mol/L, pH9.5) after stopping, by radioactivity triacylglycerol product separation in organic facies, and with the alkaline ethanol solution (ethanol: 0.5NNaOH:H of 2.0mL
2o=50:10:40) washing once.The radioactivity detecting upper strata heptane layer by liquid scintillation photographic process quantizes DGAT1 activity.Experimental result is as follows:
| Component | IC 50 (μg/mL) |
| Active component of the present invention | 11.8 |
Experimental result shows, and when active component concentration of the present invention is 11.8 μ g/mL, DGAT1 activity is had to the inhibitory action (IC of 50%
50).
test example 2
active component of the present invention falls body weight experiment to hyperlipemia rat
Get the Kunming kind male rat 50 of healthy cleaning grade, normal feedstuff balance is fed after 7d, filters out the rat 40 that body weight is 160-220g, random packet become blank group, model group, experimental group (CWJ), Xuezhikang matched group (XZK).Rat forms hyperlipidemia animal model by feeding high lipid food.To end from experiment, normal group and hyperlipidemia model group give equal-volume normal saline, and administration group and matched group gastric infusion Radix Et Caulis Acanthopanacis Senticosi active component (200mg/kg) and Xuezhikang (100mg/kg) respectively, 1 time/d, continuous gavage 30d, every day measures body weight.Experimental result is as follows:
| Group | Experiment starts previous body weight value (g) | Body weight value (g) after off-test |
| Blank group | 179 | 321 |
| Model group | 245 | 388 |
| The active group of CWJ | 242 | 359 |
| XZK matched group | 238 | 357 |
Experimental result shows, and experimental group compares with model group, and Radix Et Caulis Acanthopanacis Senticosi active component has hyperlipemia rat caused by high fat diet falls body weight effect significantly, and it is suitable with Xuezhikang matched group that it falls body weight effect.
test example 3
active component of the present invention is on the impact of hyperlipemia rat serum TG, TC and HDL-C content
Experimental group gavage is to Radix Et Caulis Acanthopanacis Senticosi active component (200mg/kg) of the present invention; Normal group and hyperlipidemia model group give equal-volume normal saline, matched group gastric infusion Xuezhikang (100mg/kg), 1 time/d, after continuous gavage 30d, blood is got in docking, measures the content of serum cholesterol (TC), serum triglycerides (TG) and serum High Density Lipoprotein Cholesterol (HDL-C).Experimental result is as follows:
| Group | TG （mmol/L） | TC（mmol/L） | HDL-C（mmol/L） |
| Blank group | 0.94 | 1.42 | 0.96 |
| Model group | 2.44 | 2.62 | 0.66 |
| The active group of CWJ | 1.53 | 2.16 | 0.80 |
| XZK group | 1.25 | 1.93 | 0.91 |
Experimental result shows, and hyperlipemia rat serum TG and TC level caused by remarkable low high fat diet can fall in active component CWJ of the present invention, improves rat blood serum HDL-C concentration, and make it level off to normal level, this shows that this active component has good hypolipemic function.
test example 4
active component of the present invention is on the impact of hyperlipemia rat serum MDA, SOD and GSH-Px vigor
Experimental group is with active component gastric infusion (200mg/kg) of the present invention; Normal group and hyperlipidemia model group give equal-volume normal saline, matched group gastric infusion Xuezhikang (100mg/kg), 1 time/d, after continuous gavage 30d, blood is got in docking, measures Serum MDA (MDA) content, serum superoxide dismutases (SOD) content and whole blood Glutathione peroxidase (GSH-Px) vigor.Experimental result is as follows:
| Group | MDA（mmol/mL） | SOD （U/mL） | GSH-Px（U/mL） |
| Blank group | 6.20 | 234.60 | 1592.42 |
| Model group | 11.80 | 181.73 | 1024.84 |
| The active group of CWJ | 6.57 | 219.42 | 1442.24 |
| XZK group | 6.19 | 222.56 | 1424.13 |
Experimental result shows, gastric infusion active component of the present invention, and can significantly improve the vigor of SOD in rat blood serum in pole, and can significantly reduce MDA content in rat blood serum, it is better than Xuezhikang matched group to the lifting effect of GSH-Px vigor.
the evaluation of experimental result and explanation:hyperlipemia mainly refers to that serum cholesterol (TC), triglyceride (TG) are higher than positive dyslipidemic disorders.According to injury response theory, first atherosclerosis makes the inner membrance of tremulous pulse sustain damage by hyperlipidemia to cause, and atherosclerotic generation and development and serum TC, TG level are relevant.High density lipoprotein (HDL) is considered to a kind of antiatherogenic lipoprotein, its mechanism of action is the carrier serving as antiport cholesterol, the deposition and removing cholesterol of restriction tremulous pulse cholesterol play an important role, in blood, HDL-C level becomes negative correlation with Incidence of CHD, in patients with coronary heart disease, HDL-C accounts for 30% ~ 50% lower than normal limits value person, therefore reduce TC, TG content in serum, improve HDL-C content most important with treatment hyperlipidemia, atherosclerosis and complication thereof to prevention.DGAT1 gene knockout and use in the research of DGAT1 inhibitor to animal pattern, in DGAT1 gene knockout or body, the suppressed body that all can make of DGAT1 increases the sensitivity of leptin, thus increase energy expenditure and improve carbohydrate metabolism, significantly reduction small intestinal and adipose cell, to the absorption of triacylglycerol and synthesis, reduce the content of the triacylglycerol in body from source in addition.
Test data shows active component of the present invention significantly suppression DGAT1 activity (test example 1); And body weight experiment (test example 2) is fallen by hyperlipemia rat, affirm fully it reduces body weight effect to hyperlipidemia model animal; By hyperlipemia rat serum TG, TC and HDL-C changes of contents (test example 3), proved invention active component significantly can reduce TC, TG level in hyperlipemia in mice serum, improves HDL-C in serum active; Hyperlipemia rat serum MDA, SOD and GSH-Px vigour changes (test example 4), show what active component of the present invention may have anti-free radical effects, thus improve the oxidation resistance of body, alleviate lipid peroxidation class material to the murder by poisoning of body.Comprehensive above-mentioned correlation test data, show that Radix Ginseng active component of the present invention has potential practical significance to treatment and prevention hyperlipemia, atherosclerosis, obesity and complication.
good effect of the present invention is:from Araliaceae Acanthopanax Radix Et Caulis Acanthopanacis Senticosi (
radixAcanthopanacisSenticosl) in the active component that obtains of extracting and developing have and suppress the effect of DGAT1, can in preparation hyperlipidemia, atherosclerosis, obesity and complication medicinal application, significant to the resources of medicinal plant developing China.
Detailed description of the invention
Following examples are intended to illustrate further, instead of restriction the present invention.Without prejudice under the prerequisite of the spirit and principles in the present invention, any change that the indivedual technical step of invention is carried out and changed and all will fall into accompanying claims scope of the present invention.Below in conjunction with concrete embodiment, the present invention is set forth further, but do not limit the present invention.
embodiment 1
By 75% soak with ethanol 1 hour of Radix Et Caulis Acanthopanacis Senticosi 1-2 times amount, utilize ultrasonic extraction 1-3 hour, sucking filtration also collects filtrate; Filtrate concentrates with Rotary Evaporators, collects concentrated solution, cools, add 2-3 times of water gaging and stir, room temperature leaves standstill 24 hours, separates out precipitation, and filter or centrifuging and taking precipitation, precipitate is placed in surface plate and heats, removing second alcohol and water, until without alcohol taste, obtains Radix Et Caulis Acanthopanacis Senticosi ethanol extract; By Radix Et Caulis Acanthopanacis Senticosi ethanol extract through 150 μm of reversed phase chromatography, in order to methanol/water (V/V, 0:10-10:0) for mobile phase carries out gradient elution, the separation component collected utilizes inverse thin layer chromatography to detect, the identical separation component of composition merges, concentrate after obtain 10 separation components (F1-F10).By F2 component again through HP-20 macropore chromatograph, in order to methanol/water (V/V, 0:10-10:0) for mobile phase carries out gradient elution, collect the separation component of methanol/water (V/V, 3:7), concentrated after obtain Radix Et Caulis Acanthopanacis Senticosi active component.
embodiment 2
According to the conventional method of pharmaceutics, by dry for active component obtained for embodiment 1, one or more pharmaceutically acceptable carrier or mixed with excipients can be added, are prepared into the various various regular dosage forms be applicable to through gastrointestinal tract administration.As, conventionally incapsulate aseptic for as above obtained dry powder, both obtained the active component medicine of the present invention of capsule formulation.According to method known in pharmaceuticals industry, active component of the present invention may be made tablet, capsule, pill, powder agent, suppository and solution and suspending agent.Wherein be preferably applied in capsule and the tablet of gastrointestinal administration.When preparation is applicable to oral administered dosage form, sucrose, lactose, galactose, corn starch, gelatin, microcrystalline Cellulose, carboxymethyl cellulose etc. can be used as carrier or excipient.
Claims (5)
1. one kind has the preparation method of the Radix Et Caulis Acanthopanacis Senticosi active component of effect for reducing blood fat.
2. as requested 1 pharmaceutical composition in the preparation method of Radix Et Caulis Acanthopanacis Senticosi ethanol extract, comprise the following steps:
(1) take Radix Et Caulis Acanthopanacis Senticosi 300g, add 1-2 75% soak with ethanol doubly 1 hour, utilize ultrasonic extraction 1-3 hour, sucking filtration also collects filtrate;
(2) filtrate concentrates with Rotary Evaporators, collects concentrated solution, cools, add 2-3 times of water gaging and stir, room temperature leaves standstill 24 hours, separates out precipitation, and filter or centrifuging and taking precipitation, precipitate is placed in surface plate and heats, removing second alcohol and water, until without alcohol taste, obtains Radix Et Caulis Acanthopanacis Senticosi ethanol extract;
(3) be dissolved in 1.0-0.6L water by Radix Et Caulis Acanthopanacis Senticosi ethanol extract, use 3.0-2.0L n-hexane extraction after becoming suspension, collection water layer extract, concentrating under reduced pressure become extractum;
(4) by Radix Et Caulis Acanthopanacis Senticosi ethanol extract through 150 μm of reversed phase chromatography; in order to methanol/water (V/V; 0:10-10:0) for mobile phase carries out gradient elution; the separation component collected utilizes inverse thin layer chromatography to detect, the identical separation component of composition merges, concentrate after obtain 10 separation components (F1-F10);
(5) by F2 component, be mobile phase by methanol/water (V/V, 0:10-10:0), carry out gradient elution, collect the separation component of methanol/water (V/V, 3:7), concentrated after obtain Radix Et Caulis Acanthopanacis Senticosi active component.
3. method according to claim 1, is characterized in that Radix Et Caulis Acanthopanacis Senticosi active component reflux, extract, Organic Alcohol concentration used is less than or equal to 75%.
4. Radix Et Caulis Acanthopanacis Senticosi active component is being treated and is preventing to apply in various hyperlipidemia, atherosclerosis and complication medicine thereof according to claim 1.
5. Radix Et Caulis Acanthopanacis Senticosi active component falls body weight purposes in disorders of lipid metabolism according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410287181.0A CN105193886A (en) | 2014-06-25 | 2014-06-25 | Preparation method and medical application of blood-fat-reducing active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410287181.0A CN105193886A (en) | 2014-06-25 | 2014-06-25 | Preparation method and medical application of blood-fat-reducing active component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105193886A true CN105193886A (en) | 2015-12-30 |
Family
ID=54942076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410287181.0A Pending CN105193886A (en) | 2014-06-25 | 2014-06-25 | Preparation method and medical application of blood-fat-reducing active component |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105193886A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110283156A (en) * | 2019-07-29 | 2019-09-27 | 河北省农林科学院经济作物研究所 | The novel reducing blood lipid compound extracted from wilsonii |
| CN110680850A (en) * | 2019-12-02 | 2020-01-14 | 黑龙江中医药大学 | Traditional Chinese medicine health product for reducing blood fat |
| CN112603922A (en) * | 2020-12-24 | 2021-04-06 | 北华大学 | Application of lignan glycoside compounds in preparation of lipid-lowering drugs |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040055829A (en) * | 2002-12-23 | 2004-06-30 | 박진우 | Lipoprotein lipase activating effect of some Acanthopanax species and its use as anti-hyperlipidemic materials for medicinal drug and functional food |
| CN1634489A (en) * | 2004-12-03 | 2005-07-06 | 张平 | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN102579532A (en) * | 2011-10-17 | 2012-07-18 | 哈尔滨珍宝制药有限公司 | Radix acanthopanacis senticosl composition, preparation containing composition and detection method of preparation |
| CN103239493A (en) * | 2013-05-27 | 2013-08-14 | 北华大学 | Pharmaceutical composition for reducing blood sugar and preparation method thereof |
-
2014
- 2014-06-25 CN CN201410287181.0A patent/CN105193886A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040055829A (en) * | 2002-12-23 | 2004-06-30 | 박진우 | Lipoprotein lipase activating effect of some Acanthopanax species and its use as anti-hyperlipidemic materials for medicinal drug and functional food |
| CN1634489A (en) * | 2004-12-03 | 2005-07-06 | 张平 | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN102579532A (en) * | 2011-10-17 | 2012-07-18 | 哈尔滨珍宝制药有限公司 | Radix acanthopanacis senticosl composition, preparation containing composition and detection method of preparation |
| CN103239493A (en) * | 2013-05-27 | 2013-08-14 | 北华大学 | Pharmaceutical composition for reducing blood sugar and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 区中原等: "刺五加总苷提取工艺研究", 《哈尔滨商业大学学报（自然科学版）》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110283156A (en) * | 2019-07-29 | 2019-09-27 | 河北省农林科学院经济作物研究所 | The novel reducing blood lipid compound extracted from wilsonii |
| CN110283156B (en) * | 2019-07-29 | 2020-06-30 | 河北省农林科学院经济作物研究所 | Novel hypolipidemic compound extracted from acanthopanax senticosus |
| CN110680850A (en) * | 2019-12-02 | 2020-01-14 | 黑龙江中医药大学 | Traditional Chinese medicine health product for reducing blood fat |
| CN112603922A (en) * | 2020-12-24 | 2021-04-06 | 北华大学 | Application of lignan glycoside compounds in preparation of lipid-lowering drugs |
| CN115006417A (en) * | 2020-12-24 | 2022-09-06 | 北华大学 | Application of lignan glycoside compounds in preparation of lipid-lowering drugs |
| CN115006417B (en) * | 2020-12-24 | 2023-10-13 | 北华大学 | Application of lignan glycoside compounds in preparation of lipid-lowering drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| CN102319275B (en) | Sunset abelmoschus flower extract, preparation and preparation method thereof | |
| EP2246047B1 (en) | Use of lanostane derivatives in treating cachexia | |
| CN112472729B (en) | Application of caulis sinomenii in preparing medicine for treating human glioma | |
| CN105193886A (en) | Preparation method and medical application of blood-fat-reducing active component | |
| US10093695B2 (en) | Sterol derivative, preparation method therefor and use thereof | |
| CN104224863B (en) | Lysimachia herb total flavone is preparing the application in treating antihyperuricemic disease drug | |
| CN104788518A (en) | Preparation method for quercetin-3-O-beta-D-glucoside and use of quercetin-3-O-beta-D-glucoside in lipid regulation | |
| CN103360452B (en) | The Synthesis and applications of Muskmelon Base tetracyclic triterpene cucurbitane compound | |
| CN102357110B (en) | New application of Eclipta prostrata L in preparing medicine for preventing and treating hyperlipidemia | |
| WO2013159751A1 (en) | Pharmaceutical composition, preparation method and use thereof | |
| CN104873616B (en) | Application of the litchi rind polyphenol in the medicine or health products that reduce liver tg is prepared | |
| CN103922908A (en) | Preparation method of lignin compound with blood lipid reduction effect and medicinal application thereof | |
| CN103877136A (en) | Preparation method and medicinal application of blood fat-reducing active component | |
| CN106138164A (en) | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function | |
| CN102614222B (en) | Preparation method of sea cucumber extract rich in triterpene sapogenin | |
| CN105534971B (en) | Dibenzo oxepin class compound screens or prepares in vitro the application in drug | |
| CN103919826A (en) | Method for preparing medicinal composition for reducing blood fat and medical application | |
| CN113952417A (en) | Preparation method of dry dendrobium alcohol extract for spontaneous hypertension | |
| CN107028965A (en) | Application and product of the yuenkanin or derivatives thereof in fat-reducing medicament is prepared | |
| CN105456277A (en) | Application of active part of ganoderma triterpene acid in preparing hypolipidemic health care products and drugs | |
| CN112843111A (en) | Pharmaceutical composition for treating metabolism-related fatty liver disease and preparation method and application thereof | |
| CN108524574A (en) | A kind of Dendranthema indicum extract and application | |
| CN101785816A (en) | Grass-leaved sweetflag extract, medicine composition with grass-leaved sweetflag extract, preparation method and application thereof | |
| CN104922271B (en) | Application of the litchi rind polyphenol in the medicine or health products that reduce hepatic cholesterol is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151230 |